Title: Public-Private Partnerships for Drug Discovery: The National Institute of Mental Health Perspective

In late 2014, the CINP published the report of a summit convened to identify various ways to move forward in drug development for CNS disorders (Andersen et al., Nature Reviews Drug Discovery, 13:871). One component of this report included a recommendation for furtherance of Public-Private Partnerships (PPPs) to foster efforts toward development of new compounds for treatment of CNS disorders. These PPPs could facilitate such areas as biomarker development, validation of tests for measuring specific aspects of functioning in clinical trials, and identification of new targets for drug discovery.

The National Institute of Mental Health (NIMH) has participated in PPPs for several decades in order to advance research on new treatment development. Perhaps the best known of these PPPs is the MATRICS project (Measurement and Treatment Research to Improve Cognition in Schizophrenia). This program was a joint effort of the NIMH, US Food and Drug Administration (FDA), academic investigators, and industry representative, and had as notable outcomes the development of the MCCB MATRICS Consensus Cognitive Battery) and a willingness by FDA the to consider cognition as a specific indication within schizophrenia (a development that is echoed in current international activity regarding potential indications for cognition in depression).

The purpose of this talk is to review the status and goals of current NIMH PPPs with respect to drug discovery. These efforts span the range of biomarker validation, development of new functional measures, and programs involving new target identification. In addition, specific aspects of these partnerships are aligned with the NIMH Research Domain Criteria (RDOC) program to consider new approaches and measures for specific aspects of functioning and their related neural systems. These could represent within- or trans-diagnostic dimensions that provide more homogeneous groupings for research in new drug development and clinical trials.
